How common addiction medicines work in Australia

Addiction medicines are not substitutes for treating the person rather than the substance. They can stabilise brain chemistry, reduce withdrawal and cravings, and make activities such as work, housing and family support more achievable. For many conditions, medication is a long-term component of care rather than a brief detox or one-off cure. It can also break a cycle in which stress, pain and loss of control continue driving harmful use.

Understanding the mechanism of action of common addiction medications helps pharmacists explain benefits, side effects and risks in plain language. It also supports safer dispensing, because the same receptor effects that reduce craving can alter pain relief, interact with sedatives or create problems if treatment starts too soon.

Australian pharmacy teams need this knowledge alongside non-judgemental conversations and practical access to care. People may call a pharmacy a “chemist” and a prescription a “script,” but clinical terminology should remain clear and respectful. PBS access, naloxone availability and local treatment services all shape how medicines are used here.

Opioid receptors and the reward pathway

Opioids bind mainly to μ-opioid receptors in areas of the brain and body involved in pain, stress and reward. These receptors usually respond to the body’s own opioids. Medicines such as methadone and buprenorphine activate them in a controlled way, reducing the neural signal that drives craving and painful withdrawal.

At the cellular level, μ receptors inhibit neuronal activity. On GABA neurons in the reward pathway, this reduces inhibitory GABA release and can increase dopamine signalling. Repeated opioid exposure then adapts the system, so the same dose may produce less effect and the body may need more to avoid withdrawal. Tolerance is a physiological adaptation, not evidence that a person is seeking attention.

This distinction matters in opioid use disorder, where altered brain function and compulsive opioid-seeking coexist. Opioid Agonist Treatment (OAT) supplies a measured agonist at regular intervals to maintain stable receptor occupancy. That stabilises the system rather than repeatedly allowing the highs and lows associated with uncontrolled use.

Agonists, partial agonists and antagonists

Methadone is a full μ-opioid agonist with a long and variable half-life. At an adequate maintenance dose, it prevents withdrawal and suppresses craving without the rapid intoxication associated with an opioid spike. Its slow onset and long duration also make dosing errors dangerous: too much can accumulate and suppress breathing, particularly with alcohol, benzodiazepines or other sedatives. Clinicians therefore adjust it cautiously, as a stable level is safer than repeatedly chasing immediate effects.

Buprenorphine is a high-affinity partial agonist. It occupies μ receptors strongly but activates them less than a full agonist, giving it a lower ceiling on respiratory depression in many circumstances. High receptor affinity also helps block the effects of other opioids. Because buprenorphine can displace a full agonist while producing less effect, standard induction during active withdrawal may cause precipitated withdrawal. Prescribers may use an overlap or “microinduction” strategy when appropriate.

Naltrexone is a competitive opioid antagonist: it blocks rather than activates opioid receptors, so opioids cannot produce their usual effects. It requires an opioid-free interval verified by the prescriber, often at least seven days after short-acting opioids and longer after buprenorphine. People who require opioid analgesia need a prescriber-supported plan because naltrexone can block pain relief. Naloxone is also an antagonist, but short-acting and used for emergency reversal of suspected overdose. Repeated doses may be needed because its effect can wear off before the opioid does.

Alcohol and nicotine medicines

For alcohol use disorder, disulfiram inhibits aldehyde dehydrogenase, causing acetaldehyde to accumulate if someone drinks. The resulting flushing, nausea and discomfort are intended to discourage drinking; disulfiram does not directly reduce craving and can cause serious liver injury. It requires informed consent and careful screening. Acamprosate works differently, modulating excessive glutamatergic activity in the brain and supporting abstinence over time.

Nicotine replacement therapy gives a slower, lower dose of nicotine than smoking, easing withdrawal while avoiding combustion and rapid delivery to the brain. Patches provide steady levels, while gum or lozenges allow intermittent use. Combining forms can sometimes improve control of breakthrough cravings. Varenicline partially activates nicotinic α4β2 receptors, reducing cravings and withdrawal; bupropion is an antidepressant that increases noradrenaline and dopamine signalling.

Australia has no routinely approved medicine specifically for stimulant use disorder, so treatment is usually individualised and may include psychological therapy, peer support, harm reduction and care for co-occurring conditions. Off-label stimulants sometimes appear in research or specialist care, but they are not a substitute for a clear treatment plan, monitoring and informed consent.

Clinical checks that prevent avoidable harm

Mechanism-based knowledge becomes useful at the counter only when it is translated into a patient-specific review. Pharmacists should reconcile the medicine list and ask about substances that may not appear on it.

Core medication checks

Current prescribed and non-prescribed medicines, supplements, alcohol and other drugs.
Last opioid or alcohol use, withdrawal pattern, tolerance and any opioid-free interval.
Liver and kidney function, pregnancy, breathing conditions and mental health history.
Treatment goals, consent, privacy, supports and the agreed review date.

A second check turns pharmacology into practical instructions, especially when the medicine is taken at home.

Questions for safe use

How and when should the medicine be taken, and what should happen after a missed dose?
Which activities need caution, particularly driving or mixing with alcohol?
Where is the medicine stored, and can someone else reach the naloxone emergency plan?
Which symptoms mean urgent medical help is needed?

Not every illness during addiction treatment is withdrawal. Fever, a spreading rash, confusion, severe pain or breathing difficulty needs assessment rather than assumption. Likewise, fever and rash after travel should not be labelled withdrawal without investigation; a Rift Valley fever review shows why one travel-related cause can require testing and public-health advice.

Community pharmacy care across Australia

The Pharmaceutical Benefits Scheme (PBS) subsidises many listed medicines, including medicines used in addiction treatment, although eligibility and listings change. OAT is delivered through public services, specialist prescribers and community pharmacies, with some doses supervised on site. The Australian habit of saying “script” is useful shorthand, but a prescription, a repeat and a pharmacy pickup are not interchangeable processes. Pharmacists should check current PBS criteria rather than assume every medicine is subsidised.

Naloxone has been PBS-listed and available without a prescription nationally since 1 January 2025, making a pharmacy an important access point for take-home spray and injection forms. Availability can still vary by product and location. Pharmacists can demonstrate use, identify where emergency help is available and discuss how a family member or trusted support person can respond if the person is unresponsive. Naloxone should never delay calling 000 when a suspected overdose is present.

Harm-reduction services sit alongside treatment. The medically supervised injecting facility at North Richmond Health Hub in Melbourne and the Kings Cross facility in Sydney provide drug checking, sterile equipment and connections to care. These services also demonstrate that a response to drug harm need not rely only on abstinence or punishment; it can keep people alive and engaged with health services.

Access is not equal everywhere. Aboriginal and Torres Strait Islander clients may face distance, stock shortages, past discrimination and services that fail to provide culturally safe care. Aboriginal Medical Services, Aboriginal health workers, local community pharmacies and telehealth can help, but pathways should be designed with communities rather than applied as a single national template. National policy is useful when translated into local relationships, a recurring theme in community pharmacy perspectives.

Turning knowledge into coordinated care

The right medicine depends on the substance, pattern of use, health status, preferences and level of support. Goals may include stopping use, reducing harm, managing a long-term condition or simply stabilising enough to attend other care. Pharmacists can monitor response, adverse effects and function, then communicate changes to the prescriber rather than leaving the person to negotiate several services alone. Shared decision-making also makes it easier to identify when a person is not taking a medicine as prescribed and to address the reason without blame.

Collaboration is especially important when pain, mental health, alcohol use and opioid use overlap. A Home Medicines Review can identify duplicate or interacting medicines, while referral pathways connect people with addiction specialists, social workers, peer workers and suicide-prevention services. Consent and confidentiality should be respected, and urgent risks such as suicidal thinking, delirium or suspected overdose should be escalated under local protocols.

Pharmacists, prescribers, consumers and support people can act now by including a confidential medication review in the next appointment, checking local treatment pathways and confirming that naloxone is accessible when opioids are involved. If there is immediate danger or a suspected overdose, call 000.